JP2022533433A5 - - Google Patents

Info

Publication number
JP2022533433A5
JP2022533433A5 JP2021569359A JP2021569359A JP2022533433A5 JP 2022533433 A5 JP2022533433 A5 JP 2022533433A5 JP 2021569359 A JP2021569359 A JP 2021569359A JP 2021569359 A JP2021569359 A JP 2021569359A JP 2022533433 A5 JP2022533433 A5 JP 2022533433A5
Authority
JP
Japan
Application number
JP2021569359A
Other languages
Japanese (ja)
Other versions
JP7623958B2 (ja
JPWO2020239568A5 (https=
JP2022533433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/064046 external-priority patent/WO2020239568A1/en
Publication of JP2022533433A publication Critical patent/JP2022533433A/ja
Publication of JPWO2020239568A5 publication Critical patent/JPWO2020239568A5/ja
Publication of JP2022533433A5 publication Critical patent/JP2022533433A5/ja
Application granted granted Critical
Publication of JP7623958B2 publication Critical patent/JP7623958B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569359A 2019-05-24 2020-05-20 [2-(3-フルオロ-5-メタンスルホニルフェノキシ)エチル](プロピル)アミンの薬学的に許容される塩、およびその使用 Active JP7623958B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19176514.8 2019-05-24
EP19176514 2019-05-24
EP20166361.4 2020-03-27
EP20166361 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (4)

Publication Number Publication Date
JP2022533433A JP2022533433A (ja) 2022-07-22
JPWO2020239568A5 JPWO2020239568A5 (https=) 2023-05-29
JP2022533433A5 true JP2022533433A5 (https=) 2023-05-29
JP7623958B2 JP7623958B2 (ja) 2025-01-29

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569359A Active JP7623958B2 (ja) 2019-05-24 2020-05-20 [2-(3-フルオロ-5-メタンスルホニルフェノキシ)エチル](プロピル)アミンの薬学的に許容される塩、およびその使用

Country Status (21)

Country Link
US (2) US12275694B2 (https=)
EP (2) EP4292653B1 (https=)
JP (1) JP7623958B2 (https=)
KR (1) KR102892833B1 (https=)
CN (1) CN113853369B (https=)
AU (1) AU2020286003B2 (https=)
BR (1) BR112021023563A2 (https=)
CA (1) CA3140805A1 (https=)
CL (1) CL2021003115A1 (https=)
CO (1) CO2021016556A2 (https=)
DK (1) DK3976581T3 (https=)
ES (1) ES2970361T3 (https=)
FI (1) FI3976581T3 (https=)
IL (1) IL288271B2 (https=)
JO (1) JOP20210312A1 (https=)
MX (1) MX2021014271A (https=)
PH (1) PH12021552844A1 (https=)
PL (1) PL3976581T3 (https=)
PT (1) PT3976581T (https=)
SG (1) SG11202112165QA (https=)
WO (1) WO2020239568A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3976581T3 (fi) 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat
CN116685314A (zh) * 2020-11-10 2023-09-01 综合研究实验室瑞典股份公司 用于预防或减轻对用于帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺(美多培坦)
EP4577201A1 (en) * 2022-08-24 2025-07-02 Alkem Laboratories Limited Mesdopetam compositions
WO2024062344A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof
GB202312055D0 (en) 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51123821A (en) 1975-04-18 1976-10-28 Nippon Kayaku Co Ltd An algicide and protective agent
US4128574A (en) * 1976-10-04 1978-12-05 General Electric Company Method for making organic polycarboxylic acids
GB8823405D0 (en) 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
PT707007E (pt) 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
JP2006193494A (ja) 2005-01-17 2006-07-27 Dainippon Ink & Chem Inc 4級アンモニウム系化合物を有効成分とする心臓疾患治療剤
KR20080036957A (ko) 2005-06-23 2008-04-29 아스트라제네카 아베 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체
WO2007063789A1 (ja) 2005-11-29 2007-06-07 Kissei Pharmaceutical Co., Ltd. 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2007072041A1 (en) 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
NZ570633A (en) * 2006-02-15 2011-12-22 Ms Science Corp Flurophenoxy-piperazine derivatives
WO2008153958A2 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
EP2271638B1 (en) 2008-04-29 2011-08-31 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
WO2009133109A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
AU2009242092A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2699543B1 (en) 2011-04-19 2016-03-02 Integrative Research Laboratories Sweden AB Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
CN117304079A (zh) 2016-02-08 2023-12-29 默克专利股份有限公司 N-(4,5-双甲磺酰基-2-甲基苯甲酰基)胍盐酸盐和n-(4,5-双甲磺酰基-2-甲基苯甲酰基)胍盐的结晶变体
ES2943252T3 (es) 2017-05-19 2023-06-12 Integrative Res Laboratories Sweden Ab Fumarato de (+)-3-(2,3-difluorofenil)-3-metoxipirrolidina, un proceso para su preparación y sus usos
MX2020001311A (es) * 2017-08-07 2020-03-20 Suven Life Sciences Ltd Compuestos de fluoropiperidina como antagonistas del receptor 5-hidroxitriptamina 6 puro.
WO2020110128A1 (en) 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
FI3976581T3 (fi) 2019-05-24 2024-01-31 Irl 790 Ab [2-(3-fluori-5-metaani-sulfonyylifenoksi)etyyli](propyli)amiinin viinihapposuolat

Similar Documents

Publication Publication Date Title
JP2022533433A5 (https=)
JP2023548429A5 (https=)
BR102021012571A2 (https=)
RU2020100691A3 (https=)
CN305533039S (https=)
CN305535293S (https=)
CN305759810S (https=)
CN305536909S (https=)
CN305536783S (https=)
CN305536070S (https=)
CN305534504S (https=)
CN305530745S (https=)
CN305530159S (https=)
CN305528855S (https=)
CN305528806S (https=)
CN305528669S (https=)
CN305528346S (https=)
CN305526837S (https=)
CN305892892S (https=)
CN305808493S (https=)
CN305805618S (https=)
CN305804210S (https=)
CN305802443S (https=)
CN305801293S (https=)
CN305800041S (https=)